摘要
目的评价培维索孟治疗肢端肥大症的疗效和安全性。方法系统性检索Cochrane Library、Medline、Embase、中国知网、维普等数据库,对培维索孟治疗肢端肥大症的疗效和安全性进行描述性的系统评价。结果 1培维索孟能缓解患者部分症状;2培维索孟能使患者血清胰岛素生长因子-1(IGF-1)明显降低,同时生长激素可能升高;3培维索孟不影响肿瘤大小;4培维索孟短期不良反应较少。结论培维索孟能改善肢端肥大症患者的症状,有效降低血清IGF-1水平,短期使用有较好的安全性。
ObjectiveTo evaluate the effectiveness and safety of treatment of acromegaly with pegvisomant.MethodsThedatabases including Cochrane Library, Medline, EMbase, CNKI and VIP were searched to collect randomized controlled trials oftreatment of acromegaly with pegvisomant. The effectiveness and safety of pegvisomant for acromegaly were reviewed by narrativesynthesis.Results 1 The signs and symptoms could be improved by pegvisomant in the patients with acromegaly. 2 The serum level ofinsulin-like growth factor（IGF-1） could be significantly reduced and the serum level of growth hormone could be significantly increasedby pegvisomant. 3 The pituitary growth hormone-secreting adenomas volume were unchanged after treatment with pegvisomant in thepatients with acromegaly.ConclusionPegvisoment may effectively reduce serum IGF-1 levels and improve the signs and symptoms inthe patients with acromegaly. The short-term use of pegvisomant is safe in the patients with acromegaly.
出处
《中国临床神经外科杂志》
2015年第10期591-593,共3页
Chinese Journal of Clinical Neurosurgery
基金
四川省科技厅科技支撑计划(2014SZ0019-9
2015SZ0120)
